Durect fails alcohol-associated hepatitis trial, plans phase 3 anyway as investors scorch stock

Durect and investors have reached radically different conclusions about its severe alcohol-associated hepatitis phase 2 data. The biotech hailed “remarkable” results—on a secondary goal, in a subpopulation—but failed to persuade investors to look past the failure of the primary endpoint, causing its stock to sink.